Initiation of Methadone in primary care (ANRS-Methaville). A phase III randomized intervention trial

Publié le 5 Novembre 2012
Mis à jour le 05 Juillet 2019

BACKGROUND: In France, the rapid scale-up of buprenorphine, an opioid maintenance treatment (OMT), in primary care for drug users has led to an impressive reduction in HIV prevalence among injecting drug users (IDU) but has had no major effect on Hepatitis C incidence. To date, patients willing to start methadone can only do so in a methadone clinic (a standard centre for drug and alcohol dependence (CSAPA) or a hospital setting) and are referred to primary care physicians after dose stabilization. This study aims to assess the effectiveness of methadone in patients who initiated treatment in primary care compared with those who initiated it in a CSAPA, by measuring abstinence from illicit opioid use after one year of treatment. METHODS: The ANRS-Methaville study is a randomized multicenter non-inferiority control trial comparing methadone initiation (lasting approximately 2 weeks) in primary care and in CSAPA. The model of care chosen for methadone initiation in primary care was based on study-specific pre-training of all physicians, exclusion criteria and daily supervision of methadone during the initiation phase. Between January 2009 and January 2011, 12 sites each having one CSAPA and several primary care physicians, were identified to recruit patients to be randomized into two groups, one starting methadone in primary care (n=147), the other in CSAPA (n=49). The primary outcome of the study is the proportion of participants not using street opioids after 1 year of treatment i.e. non-inferiority of primary care model in terms of the proportion of patients not using street opioids compared with the proportion observed in those starting methadone in a CSAPA. DISCUSSION: The ANRS-Methaville study is the first in France to use an interventional trial to improve access to OMT for drug users. Once the non-inferiority results become available the Ministry of Health and agency for the safety of health products may change the law regarding legal prescription of methadone and make methadone initiation by trained primary care physicians possible. Clinical Trials: Number Eudract 2008-001338-28, the Identifier: NCT00657397 and the International Standard Randomised Controlled Trial Number Register ISRCTN31125511.

Auteur : Roux P, Michel L, Cohen J, Mora M, Morel A, Aubertin JF, Desenclos JC, Spire B, Carrieri PM
BMC Public Health, 2012, vol. 12, p. 488